Document Detail


Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis.
MedLine Citation:
PMID:  20920848     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Once daily dosing of aminoglycosides is widely used but is limited by the inconvenience of the slow infusion it requires and the associated three-times daily infusion of a beta-lactam. Twice daily tobramycin can be given as a slow IV bolus and may be more convenient. This study compares twice with three-times daily dosing of both tobramycin and ceftazidime.
METHODS: This was a randomised, open-label, parallel group trial. CF patients presenting with an infective exacerbation were randomised to either twice or three-times daily ceftazidime and tobramycin. Markers of treatment efficacy and safety were measured in the two groups. The primary outcome measure was improvement in FEV1.
RESULTS: 146 patients were randomised into the study. There was no significant difference in the two groups for improvement in FEV1% predicted (9.93% and 7.98% for twice daily and three-times daily respectively) and similar times to next exacerbation. There were no differences in the incidence of treatment failure, nephrotoxicity and ototoxicity.
DISCUSSION: This study confirms that twice daily dosing of both tobramycin and ceftazidime is safe and effective and may be considered more convenient than current dosing schedules.
Authors:
D Adeboyeku; A L Jones; M E Hodson
Related Documents :
9573458 - Use of teicoplanin in preterm neonates with staphylococcal late-onset neonatal sepsis.
20091528 - Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fib...
2100188 - Electroretinographical changes due to antimicrobials.
6362098 - Observed differences in gentamicin pharmacokinetic parameters and dosage recommendation...
7298868 - Pharmacokinetics of levonantradol in laboratory animals and man.
7422698 - Retinotoxic effects of diaminodiphenoxybutane in rats.
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society     Volume:  10     ISSN:  1873-5010     ISO Abbreviation:  J. Cyst. Fibros.     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2011-01-18     Completed Date:  2011-05-03     Revised Date:  2011-10-17    
Medline Journal Info:
Nlm Unique ID:  101128966     Medline TA:  J Cyst Fibros     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  25-30     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
Affiliation:
North West London Hospitals NHS Trust, Central Middlesex Hospital, London, NW10 7NS, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anti-Bacterial Agents / administration & dosage,  adverse effects
Ceftazidime* / administration & dosage,  adverse effects
Cystic Fibrosis / complications*,  diagnosis
Disease Progression
Drug Administration Schedule
Drug Monitoring
Drug Therapy, Combination
Ear Diseases / chemically induced
Female
Humans
Injections, Intravenous
Kidney Diseases / chemically induced
Lung / microbiology,  pathology
Male
Pseudomonas Infections / drug therapy*,  etiology
Pseudomonas aeruginosa / drug effects*,  isolation & purification
Respiratory Function Tests
Tobramycin* / administration & dosage,  adverse effects
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents; 32986-56-4/Tobramycin; 78439-06-2/Ceftazidime
Comments/Corrections
Comment In:
J Cyst Fibros. 2011 Sep;10(5):383   [PMID:  21507733 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Absence of gender effect on amygdala volume in temporal lobe epilepsy.
Next Document:  Proteome analysis of the leukocytes from the American alligator (Alligator mississippiensis) using m...